If RNA editing could be rationally directed to mutated RNA sequences, genetic diseases caused by certain base substitutions could be treated. Here we use a synthetic complementary RNA oligonucleotide to direct the correction of a premature stop codon mutation in dystrophin RNA. The complementary RNA oligonucleotide was hybridized to a premature stop codon and the hybrid was treated with nuclear extracts containing the cellular enzyme double-stranded RNA adenosine deaminase. When the treated RNAs were translated in vitro, a dramatic increase in expression of a downstream luciferase coding region was observed. The cDNA sequence data are consistent with deamination of the adenosine in the UAG stop codon to inosine by double-stranded RNA adenosine deaminase. Injection of oligonucleotide-mRNA hybrids into Xenopus embryos also resulted in an increase in luciferase expression. These experiments demonstrate the principle of therapeutic RNA editing. RNA editing is a natural process in which an RNA sequence is modified posttranscriptionally (1, 2). We seek to correct the sequence of a mutated RNA with the goal of treating genetic diseases caused by point mutations. We term this approach therapeutic RNA editing.
RNA editing is a natural process in which an RNA sequence is modified posttranscriptionally (1, 2) . We seek to correct the sequence of a mutated RNA with the goal of treating genetic diseases caused by point mutations. We term this approach therapeutic RNA editing.
A therapeutic RNA editing reagent requires two activities: a component that specifically recognizes the sequence to be edited and a sequence modifying activity (Fig. 1) . Complementary RNA guide sequences are a component of certain natural RNA editing machinery (2, 3) . We chose a complementary oligonucleotide as a sequence recognizing component in this therapeutic RNA editing system, since complementary oligonucleotides can specifically bind to targeted sequences in cells (4) . Although the typical role of complementary oligonucleotides such as antisense DNA is to inhibit the expression of target RNAs, we designed the oligonucleotide to correct a mutated RNA (Fig. 1 ).
The second component of an editing .reagent is a sequence modifying activity. The most straightforward modifications that could alter the sequence of the mutated target RNA are nucleotide base transitions (pyrimidine to pyrimidine or purine to purine). For example, deamination can convert cytidine to uridine, and amination can convert uridine to cytidine (5) . Similarly, deamination can convert adenosine to inosine, which has base-pairing properties similar to guanosine (5) . A variety of different sequence-modifying activities could be conjugated to a therapeutic editing oligomer or activated by the hybridization of the oligonucleotide to the mutated target RNA (i.e., chemical alkylating reagents, chemical deaminating agents, or nucleotide base modifying enzymes) (6) . Fig. 1 shows a schematic outline of a therapeutic editing event in which the editing reagent binds to the targeted mutated RNA and corrects the mutated sequence by chemical or enzymatic modification. The sequence modifying activity could be an integral part of the editing reagent or could be a cellular component that is FIG. 1. Schematic representation of the general therapeutic RNA editing approach. The X represents any mutated nucleotide and the Y represents the corrected nucleotide. In this study, the base-modifying activity was the cellular double-stranded RNA adenosine deaminase (dsRAD) and the oligonucleotide was a synthetic RNA. The hybrid formed by the RNA oligonucleotide and the targeted region containing the mutated base forms a substrate for dsRAD. activated by hybridization of the oligomer. After the modification, the correcting oligonucleotide would be displaced by the potent unwinding activity of the translating ribosome (7, 8) , allowing translation of the corrected protein.
In this report, we have used complementary RNA oligonucleotides in conjunction with the cellular double-stranded RNA adenosine deaminase (dsRAD) as a base modifying activity. The ubiquitous enzyme dsRAD deaminates -50% of the adenosines to inosines in double-stranded RNA (5, 9, 10). Since inosine is similar to guanosine in its base-pairing characteristics, adenosines are functionally converted to guanosines upon deamination. Thus, a complementary RNA in conjunction with dsRAD should be able to correct certain mutated RNAs by promoting A --G transitions in the region of hybridization.
We chose a dystrophin RNA containing a premature stop codon as our initial target for correction. A portion of the dystrophin gene containing the premature stop codon was fused to a luciferase reporter gene to monitor the correction (Fig. 2) with nuclear extracts containing endogenous dsRAD. The goal was to correct the premature UAG stop codon by deamination of the adenosine to inosine. The UIG codon then would have the base-pairing properties of a UGG codon (Trp) and thus allow translation through to the downstream luciferase coding region. When the treated RNAs were translated in vitro, a dramatic increase in expression of a downstream luciferase coding region was observed. The cDNA sequence data are consistent with deamination of the adenosine in the UAG stop codon to inosine by dsRAD. Additionally, injection of oligonucleotide"mRNA hybrids into Xenopus embryos lead to increased luciferase expression. These experiments demonstrate an initial mechanism for the concept of therapeutic editing.
MATERIALS AND METHODS
Plasmid Constructs. A portion of a human dystrophin mutated sequence containing a stop codon was fused in-frame to the luciferase coding region. This fusion was cloned into the HindIll and Not I sites of pRC-CMV (Invitrogen) (11) . The initiation codon of luciferase was deleted. The sequence of the insert from the HindIlI site to the start of the luciferase coding region is (5' to 3') GCCCCTGAGGAGCGATGGAGGCCT-TGAAGGGAGGTTTGT(A/G)GAAAACTGTAAGC-CTCCAGAAAGATCTACCGCGG (4 (12) ]. A Sac II site was inserted between the dystrophin sequence and the luciferase coding region. The nucleotide in parenthesis is an adenosine in the mutant dystrophin clone and a guanosine in the positive control clone that does not contain a premature stop codon.
RNA Oligonucleotide Synthesis. RNA oligonucleotides were synthesized on an Applied Biosystems model 394 synthesizer by using phosphoramidite chemistry (13) .
In Vitro Correction Assay. Plasmids were used as templates for in vitro transcription with T7 RNA polymerase to produce dimethylguanosine-capped mRNA (Promega). The target mRNA (500 ng/p,l) was annealed to 1 ,uM complementary or irrelevant RNA oligonucleotide by heating to 70°C and slowly cooling to 37°C over 30 min. Fifty nanograms of hybrid was added to 7 ,ul ofXenopus oocyte nuclear extracts (14) , brought to a total volume of 12 Al, and incubated for 30 min at 25°C.
In the initial experiments, the hybrids were purified by ethanol precipitation, but subsequently the precipitation step was omitted to reduce variability. In the experiments shown in Fig.  3 , 1.5 ,u of the extract-treated RNA mixture was added directly to a rabbit reticulocyte lysate in vitro translation mixture and translated for 2 h by following the manufacturer's protocol (Life Technologies, Gaithersburg, MD), with an additional 1.3 mM magnesium acetate. The complementary RNA should not inhibit translation because dsRAD destabilizes duplexes by creating I-U mismatches (9, 15) . Furthermore, the translating ribosome has a potent RNA unwinding activity (7, 8) . Luciferase assays were performed on 15 ,ul of extract with the Promega luciferase assay system and luminescence was detected with a 96-well luminometer (Packard). Fifty nanograms of 20-bp poly (A)-poly(U) hybrids was added to the nuclear extracts in the competition experiments. The cDNA sequence was obtained by reverse transcription of the dystrophin region, followed by PCR. The PCR fragments were cloned and then sequenced by using a modified T7 DNA polymerase system (United States Biochemical).
Xenopus Embryo Correction Assay. Twenty fertilized Xenopus eggs for each condition were microinjected with luciferase mRNA-oligonucleotide complexes as described (see Fig. 3) ; each egg received 500 pg of complexes and 250 pg of chloramphenicol acetyltransferase (CAT) mRNA (15) . The embryos were frozen after 6 h and then lysed in 300 ,ul of reporter lysis buffer (Promega). Luminescence detection is described above and CAT was detected by the xylene extraction method (Promega).
RESULTS
To create a model system of therapeutic RNA editing, a portion of the dystrophin gene containing a premature stop codon was fused to a luciferase reporter gene (Fig. 2) . A positive control fusion clone was also constructed that contained the desired corrected stop codon [UAG (stop) -> UGG (Trp)]. In vitro-transcribed mRNA from each clone was translated in reticulocyte lysates and the translation products were assayed for luciferase activity. Without any treatment, the mutated fusion mRNA produced up to 1000-fold less luciferase activity than the corrected fusion control mRNA (T.M.W., unpublished data). The combination of low background translation through the stop codon and the high signal of luciferase detection makes this a highly sensitive assay for correction of the stop codon.
We first sought to determine whether correction of the dystrophin premature stop codon could occur in Xenopus oocyte nuclear extracts that contain high endogenous levels of dsRAD (14) . RNA oligonucleotides complementary to dystrophin and control oligonucleotides were synthesized chemically (13 Fig. 2 were annealed to an in vitro-transcribed mRNA. The hybrid was treated with nuclear extract that contains the dsRNA deaminase activity and then translated in a rabbit reticulocyte lysate and assayed for luciferase activity. The (Fig. 3A) . The completely 2'-O-methylmodified version (16) of a 34-mer oligonucleotide is not active in the correction assay, demonstrating that hybridization alone does not cause the correction (Fig. 3A) . We conclude that the complementary RNA oligonucleotides functionally corrected the stop codon mutation in the presence of nuclear extract, allowing translation through the luciferase coding region.
To confirm the correction, PCR cDNA clones derived from treated RNA were sequenced. The resulting cDNA sequences showed that the targeted adenosine in the stop codon and several surrounding adenosines were partially converted to guanosines (Fig. 4) . The pattern of modification is consistent with the sequence and position preferences of dsRAD (17) . The (Fig. 3A) , whereas the terminal modifications provide protection against exonuclease degradation (L. Beigelman, personal communication). As seen in Fig. 3A , the end-modified complementary oligonucleotide retains some correcting activity, while the scrambled control sequence has no activity. It is possible that the correcting activity of the end-modified complementary oligomer is reduced because the 2'-O-methyl modifications do not form substrates for dsRAD (Fig. 3A) . It would be useful to develop additional modified RNA chemistry that is nuclease-resistant and retains the ability to activate dsRAD to protect the internal linkages against endonuclease cleavage.
To test for correction in vivo, a Xenopus embryo microinjection system was used. Xenopus embryos contain high levels of dsRAD and microinjection allows direct delivery to the cytoplasm (9, 15). The 52-nt correcting RNA oligomer was hybridized to the mutated fusion message and the hybrids were confirmed to be active in the in vitro correction reaction described above. The samples were microinjected into onecell-stage Xenopus embryos (15) . The CAT mRNA was included in each sample to control for nonspecific effects. Six hours later the embryos were harvested and assayed for luciferase and CAT activity. Injection of the mutated dystrophin fusion hybridized with the complementary RNA oligonucleotide results in a dramatic increase in luciferase activity (Fig. 5) . Hybridization with an irrelevant RNA oligonucleotide had no effect. Expression of the positive control RNA that does not contain a stop codon was not affected by hybridization with either oligonucleotide. Furthermore, an entirely different sequence containing a premature stop codon fused to luciferase was not corrected by the dystrophin oligonucleotide. These data demonstrate that correction of the stop codon is dependent upon sequencespecific hybridization to the complementary oligonucleotide.
Comparison of the corrected signal to the cloned positive control signal indicates that roughly 35% correction occurred. We conclude that significant levels of oligonucleotide-directed correction through RNA editing can occur in cells.
DISCUSSION
This initial example of the therapeutic editing approach employed the cellular enzyme dsRAD. The enzyme dsRAD is particularly well suited for this purpose, because it has an endogenous base modifying activity that can be directed by the hybridization of a synthetic RNA oligonucleotide. Recently, it has been proposed that dsRAD is involved in a naturally occurring RNA editing event in humans (18) . Higuchi et al. (18) have found that a nucleotide in a stem-loop region in the glutamate receptor RNA is edited in a manner consistent with the activity of dsRAD. This suggests that there is sufficient dsRAD activity in some human cell types to promote substantial base modifications.
In this work, dsRAD was used to correct a premature stop codon. It is fortuitous that each of the three possible premature stop codons could be functionally changed to a tryptophan codon by adenosine deamination to inosine (UAG, UGA, or UAA to UIG, UGI, or UII). In addition to changing the stop codon, dsRAD created additional mutations in the target RNA by modifying other adenosines in the region of hybridization (Fig. 4) . However, the dystrophin protein can tolerate .;>. (Fig. 3) . The positive control dystrophin clone did not contain a premature stop codon. The "mutated control mRNA" was an unrelated sequence containing a stop codon fused to luciferase. The hybrids and control CAT mRNA were microinjected into the cytoplasm of Xenopus embryos. The embryos were lysed after 6 h and assayed for luciferase activity. The luciferase signal normalized to CAT activity is shown. The signal in the control CAT assays did not vary >33% from the mean, confirming the consistency of the microinjections. The error bars are the standard deviation of three replica luciferase assays. most point mutations that do not create stop codons (12, 18, 19) and A -> G transitions can never create a stop codon.
If therapeutic editing is to become generally useful, more precise methods of targeting the modifying activities must be developed. One method for increasing the precision of the dsRAD editing is suggested by our finding that completely 2'-O-methyl-substituted oligomers do not form substrates for dsRAD, whereas the 2'-O-methyl-end-modified oligomer has partial correcting activity. It is possible that the appropriate incorporation of 2'-O-methyl linkages might allow for more precisely targeted corrections. In this model of therapeutic editing, the base modifying activity is limited to A -> G transitions. The cellular cytidine deaminase involved in the naturally occurring C --U editing of apolipoprotein B is an additional example of a base modifying activity that may be useful for therapeutic RNA editing (20) . The sequence recognizing activity for apolipoprotein B editing appears to be a cellular protein that binds to a "mooring" sequence adjacent to the edited nucleotide. The cellular cytidine deaminase is bound to the mooring protein and is precisely directed to the edited base (21) . The expanding knowledge of natural RNA editing mechanisms provides a source of ideas for therapeutic editing applications.
While an endogenous protein enzyme catalyzed the base modification in our model of therapeutic editing, it would be useful if the catalytic activity of a targeted ribozyme could catalyze a base modification appropriate for therapeutic RNA editing. The initial ribozymes that have been characterized catalyze transesterification or cleavage of the phosphodiester backbone; however, it is now clear that the catalytic repertoire of RNA is more extensive (22) . The recent demonstration that in vitro evolution can been used to create ribozymes with new catalytic activities (22, 23) suggests that it may be possible to select for a ribozyme that catalyzes base modifications appropriate for therapeutic editing. Ribozyme-mediated therapeutic editing would not require cellular enzymes and might be more specific for the targeted base.
Two mechanisms have been employed by other groups to correct mutated RNA. Both involve RNA splicing reactions. In one case, an antisense oligomer was used in an in vitro splicing extract to block splicing at a cryptic site that was activated by a point mutation (24) . In a second approach, ribozyme technology has also been used to correct mutated RNA sequences through trans-splicing reactions catalyzed by a modified group I self-splicing intron (25) . In this approach, a corrected 3' end was spliced onto a mutated RNA. Techniques that direct splicing and techniques that permit therapeutic RNA editing represent an emerging approach to treating genetic defects in which mutations are corrected at the RNA level.
We have provided an initial example of using RNA editing to correct a mutated RNA. While there are tremendous technical challenges in extending this approach to clinical applications, growth in the understanding of natural RNA editing, along with technical advances in the field of oligonucleotide therapeutics, should facilitate efforts toward therapeutic RNA editing.
